Recent Transactions

22-Jun-05
$198 million
U.K., Switzerland flags
Target: 

Rothschilds Continuation Holdings

Hong Kong flag
Acquiror: 
Jardine Strategic Holdings

held by Royal & Sun Alliance
Advised Royal & Sun Alliance on the sale of its 21.5% shareholding in Rothschilds Continuation Holdings AG to Jardine Strategic Holdings

25-Oct-05
$2.1 billion
Germany flag
Target: 

BHW Holding AG

Germany flag
Acquiror: 
Deutsche Postbank AG

Advised BHW Holding AG, a retail financial services group, in connection with its sale to Deutsche Postbank AG, Germany’s largest retail bank

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

20-Dec-06
$424 million
Russia flag
Target: 

Aton Capital

Italy Austria flags
Acquiror: 
Bank Austria Creditanstalt / UniCredit Group

Advised Aton Capital Group, the independent Russian investment bank, on the sale of its Institutional Business to Bank Austria Creditanstalt (part of the UniCredit Group)

29-May-07
$99.1 billion
Netherlands flag
Target: 

ABN AMRO Holding NV

U.K., Spain, Belgium flags
Acquiror: 
Fortis SA/NV, The Royal Bank of Scotland Group plc, Banco Santander Central Hispano, SA

Advised Fortis on an offer by Fortis, RBS and Santander for ABN AMRO

02-Oct-07
$4.6 billion
Japan flag
Target: 

Nikko Cordial Corporation

United States flag
Acquiror: 
Citigroup, Inc.

Advised Nikko Cordial, one of Japan’s largest securities firms, on its share exchange with Citigroup Inc., which resulted in Citigroup’s acquisition of the remaining 32% of Nikko Cordial that it did not already own

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

02-Jul-08
$NA
United Kingdom flag
Target: 

NewSmith Capital

Italy flag
Acquiror: 
UniCredit SpA

Advised NewSmith Capital, an independent investment management group, on a strategic agreement with UniCredit whereby UniCredit will acquire NewSmith’s Financial Products credit advisory business, assume a 5% stake in NewSmith Capital and become an investor in NewSmith funds

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

18-May-09
$114 million
United Kingdom flag
Target: 

Close Brothers Corporate Finance Holdings Ltd.

Japan flag
Acquiror: 
Daiwa Securities SMBC Europe Ltd.

Advised Close Brothers Group plc, an independent financial services group, on the sale of its corporate finance subsidiary to Daiwa Securities SMBC Europe Ltd.

06-Jul-09
$2.0 billion
Switzerland flag
Target: 

PARIS RE Holdings Ltd.

Bermuda flag
Acquiror: 
PartnerRe Ltd.

Advised PartnerRe Ltd., a leading global reinsurer, providing multi-line reinsurance to insurance companies, on its acquisition of PARIS RE Holdings Ltd., a French-listed, Swiss-based diversified reinsurer

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

22-Apr-10
$1.9 billion
United States flag
Target: 

Bank of America Corporation

Euro flag
Acquiror: 
AXA Private Equity

Advised AXA Private Equity, a leading European diversified private equity firm, on the acquisition of a portfolio of limited partnership interests in private equity funds from Bank of America

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

29-Dec-10
$1.8 billion
Australia flag
Target: 

TOWER Australia Group Limited

Japan flag
Acquiror: 
The Dai-ichi Life Insurance Company, Limited

Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement

01-Mar-11
$128 million
Australia flag
Target: 

Tyndall Investments

Japan flag
Acquiror: 
Nikko Asset Management

Advised Suncorp, on the sale of its investment management business, Tyndall Investments, in Australia and New Zealand to Nikko Asset Management, a leading Asian mutual funds management company

11-Mar-11
$1.0 billion
Russia flag
Target: 

Troika Dialog Group Limited

Russia flag
Acquiror: 
Sberbank

Advised TD Advisors Limited, a major shareholder of Troika Dialog Group, Russia’s leading investment bank, on the sale of their stake as part of the acquisition of Troika Dialog Group by Sberbank, the largest commercial bank in Russia

21-Mar-11
$NA
United Kingdom flag
Target: 

Close Brothers Cayman Limited

Switzerland flag
Acquiror: 
Intertrust Group Holdings SA

Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA

08-Jun-11
$1.7 billion
United States flag
Target: 

Citigroup (selected private equity assets)

Euro flag
Acquiror: 
AXA Private Equity

Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup

30-Jun-11
$609 million
Japan flag
Target: 

Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion

United States flag
Acquiror: 
Royalty Pharma

Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

05-Feb-14
$NA
Sweden flag
Target: 

Unfors Raysafe AB

United States flag
Acquiror: 
Fluke Biomedical Corporation

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

05-Aug-14
$1.3 billion
U.S.A., Germany flags
Target: 

Siemens Health Services

United States flag
Acquiror: 
Cerner Corporation

Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.

11-Aug-14
$NA
United States flag
Target: 

MannKind Corporation

France flag
Acquiror: 
Sanofi

Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.

Pages

show all